Geoffrey Lawrence is research director at Reason Foundation.
Lawrence has been a financial executive in both the public and private sectors and has served as chief financial officer of publicly traded, growth stage, and startup manufacturing and distribution companies. He was CFO of Players Network, the first fully reporting, publicly traded marijuana licensee to be listed on a U.S. exchange, CFO of C Quadrant, a startup manufacturer and distributor that was subsequently sold to Lowell Farms (LOWL), CFO of Apex Extractions, a manufacturer and distributor based in Oakland that he helped take public, and, most recently, CFO of Claybourne Co., a top-3 flower brand in California by market share. Through these roles, Lawrence raised capital, planned capital expenditure, prepared financial forecasts, implemented systems for accounting and inventory control, designed internal control processes, managed monthly and quarterly closings and reporting, managed compliance with state and local regulations, negotiated contracts, and prepared filings with the U.S. Securities and Exchange Commission.
Lawrence also served as a senior appointee to the Nevada Controller’s Office, where he oversaw the state’s external financial reporting. Prior to joining Reason Foundation in 2018, Lawrence had also spent a decade as a policy analyst on labor, fiscal, and energy issues between North Carolina’s John Locke Foundation and the Nevada Policy Research Institute.
Lawrence is additionally the founder and president of an accounting and advisory firm with particular expertise in the licensed cannabis industry and public markets.
Lawrence holds an M.S. and B.S. in accounting from Western Governors University, an M.A. in international economics from American University, and a B.A. in international relations from the University of North Carolina at Pembroke. He lives in Las Vegas with his wife and two children and enjoys baseball and mixed martial arts.
-
Federal agencies’ next moves to accelerate the availability of psychedelic therapies
Federal agencies have responded to Trump's executive order on psychedelic therapies with a series of related announcements.
-
Trump’s medical marijuana rescheduling is historic—but many questions remain
The Trump administration has officially rescheduled state-licensed medical marijuana from Schedule I to Schedule III.
-
How Trump’s executive order could accelerate widespread access to psychedelic therapies
Trump's new executive order comes as states have begun taking significant action on psychedelic policy reform, positioning the federal government as a partner.
-
Model legislation for audit requirements for opioid settlement fund recipients
Reason Foundation’s new model legislation extends the single audit framework to opioid settlement fund recipients at the state level.
-
Mississippi and West Virginia to join Texas ibogaine initiative
Ibogaine may be a breakthrough therapy that enables individuals to overcome opioid addiction faster, more effectively, and at a lesser public expense.
-
Cannabusiness lawsuit highlights need for Congress to clarify federal treatment of marijuana
Without reform, lawsuits like this may force federal courts toward decisions that destabilize existing state markets or that effectively go around Congress.
-
What is 7-OH and why did the FDA seize this potentially life-saving substance?
There’s no real basis to conclude that the products are dangerous. In fact, there’s far more evidence that they may help people overcome opioid addiction.
-
Harm reduction: An evidence-based approach to the drug war
Harm reduction includes proven tools like naloxone distribution, syringe service programs, fentanyl test strip access, and supervised consumption sites.
-
The truth about marijuana, mental illness, and violence: A review of Alex Berenson’s claims in ‘Tell Your Children’
Marijuana legalization appears to reduce the prevalence of violent crime and suicide.
-
Federal court strikes down Oregon law requiring marijuana licensees to sign labor peace agreements
The judge concluded that the law would usurp powers reserved to a federal agency and that it would violate the free speech rights of marijuana business owners.
-
Drug decriminalization in Oregon: Measure 110’s impacts compared to other countries’ systems
A review of the data does not indicate any massive shift in offense rates or criminal behavior as a result of Measure 110.
-
Model legislation for optimal state regulation of hemp cannabinoids
Reason Foundation’s model legislation offers a clear and practical framework for states seeking to regulate adult-use hemp cannabinoids effectively.
-
Psychedelic treatment for neurodegenerative disorders
Recent research suggests that psychedelics, such as psilocybin and LSD, show strong potential as effective treatments for neurodegenerative disorders.
-
Debt and liquidity in America’s 10 largest cities
During fiscal year 2022, nine of America’s 10 most populous cities generated enough revenue to finance their expenditures.
-
Batch-tracking: The next wave of marijuana tracking systems
Maine recently implemented a first-of-its-kind system to track marijuana sales, setting a new standard for the industry.
-
A single cannabis retailer license type would benefit both marijuana and hemp businesses
If the tax and regulatory structure for state-licensed marijuana weren’t so restrictive, a market for hemp-derived products might never have emerged.
-
How the FDA can safely approve a promising but controversial mental health drug
The FDA’s existing processes may be able to address the advisory committee’s worries about the previous tests.
-
Marijuana rescheduling is good news, but California still needs to reduce state taxes and regulations
California lawmakers need to do their part by reducing taxes and unnecessary regulations on legal cannabis products.
